drugset / Trial / NCT05454410
Study of Efficacy, Safety, Tolerability and Pharmacokinetics of MIJ821 in Participants With Treatment- Resistant Depression (TRD)
RandomizedParallel-groupTriple-blindTreatment
Summary
The main purpose of this study was to evaluate safety and efficacy of a single injection of MIJ821 in addition to standard of care (SoC) pharmacological anti-depressant treatment in participants with treatment-resistant depression (TRD)
Timeline
- Start
- 2023-03-13
- Primary completion
- 2023-11-28
- Completion
- 2023-11-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Onfasprodil | Small molecule | 1 mg | Subcutaneous |
| Subject | Onfasprodil | Small molecule | 4 mg | Subcutaneous |
| Subject | Onfasprodil | Small molecule | 10 mg | Subcutaneous |
Indications
No indication recorded.